Acute Lymphoblastic Leukemia (ALL)

First (CR1) / Second Remission (CR2)
- Autologous or Allogeneic
  - None at this Time

Advanced Disease
- Matched Related or Unrelated Donor
  - BMT343 Phase IB T-Cell Depleted Graft Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
    - PI: Meyer
    - Sponsor: Orca Biosystems Inc.

- BMT377 Phase IIb / III in Advanced Hematologic Malignancies Undergoing Allogeneic HCT with Either Orca-T+ A-T Cell-Derived Graft w/ Additional Infusion of Conventional T Cells & Regulatory T Cells or SoC Allogenic Graft
  - PI: Meyer
  - Sponsor: Orca Biosystems Inc.

- BMT342 Phase IIIb to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
  - PI: Johnston
  - Sponsor: Fred Hutchinson

- BMT372 Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies with Either Orca-T+ A-T Cell-Derived Graft
  - PI: Meyer
  - Sponsor: Stanford University

CR / Persistent or Relapsed MRD / and Active Disease
- Matched Related
  - BMT378 Phase I Trial Evaluating the Safety of Myeloablative Conditioning Orca-T+ Allogeneic Donor-Derived CD19 / CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults w/ B-Cell Acute Lymphoblastic Leukemia (ALL)
    - PI: Meyer
    - Sponsor: Orca Biosystems

- Allogeneic
  - BMT338 Phase I DonorGrafts DerivedFrom OrcaGraft w/ GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
    - PI: Meyer
    - Sponsor: Orca Biosystems

- Haplo
  - Mismatched Unrelated

- First (CR1) or Higher Remission
  - BMT391 Phase II Hi-A-Mismatched Unrelated Donor Hematopoetic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies
    - PI: Arai
    - Sponsor: National Marrow Donor Program (NMDP)